In fact, this has been elegantly demonstrated accidentally in patients receiving the Braf inhibitor vemurafenib, which inhibits p42/44 MAPK signaling in melanoma, but can provoke squamous cell carcinoma, which has p53 mutations.14 The major discovered differences between these tumors have increased and are summarized in Table 1. This evidence concerns the gene TP53 and melanoma.